GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists

Abstract

Get full access to this article

View all access options for this article.

References

Pharmacists Letter. Comparison of GLP-1 agonists. https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2017/Jan/Comparison-of-GLP-1-Agonists-10594. Accessed March 5, 2019.

Saxenda (liraglutide) [prescribing information]. Plains-boro, NJ: Novo Nordisk Inc; September 2016.

Han

. Update regarding Tanzeum injection availability. MPR. January 26, 2018. https://www.empr.com/news/tanzeum-albiglutide-discontinued-diabetes-treatment/article/739712/. Accessed March 5, 2019.

Aroda

Rosenstock

Terauchi

, et al. Effect and safety of oral semaglutide monotherapy in type 2 diabetes—PIONEER 1 Trial. Diabetes. 2018;67(suppl 1). http://diabetes.diabetesjournals.org/content/67/Supplement_1/2-LB. Accessed March 5, 2019.

Baggio

Drucker

DJ.

Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.

MacDonald

El-kholy

Riedel

, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002; 51(suppl 3):S434-S442.

Nauck

Kleine

Orskov

Holst

Willms

Creutzfeldt

. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-744.

Nauck

Heimesaat

Behle

, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrin Metab. 2002;87(3):1239-1246.

Russell-Jones

Vaag

Schmitz

, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met SU): a randomised controlled trial. Diabetologia.2009;52(10):2046-2055.

10.

Giorgino

Benroubi

Sun

J-H

Zimmermann

Pechtner

. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care.2015;38(12):2241-2249.

11.

Marso

Daniels

Brown-Frandsen

, et al. Liraglu-tide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.

12.

American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(suppl. 1): S90-S102.

13.

Garber

Abrahamson

Barzilay

, et al. Consensus statement by the American Association of Clinical Endocri-nologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary. Endocr Pract. 2019;25:69-100.

14.

Davies

D’Alessio

Fradkin

, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41;2669-2701.

15.

Zinmann

Wanner

Lachin

, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

16.

Neal

Perkovic

Mahaffey

, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.

17.

Balena

Hensley

Miller

Barnett

AH.

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15(6):485-502.

18.

Diamant

Nauck

Shaginian

, et al. Gluca-gon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37(10):2763-2773.

19.

Lane

Weinrib

Rappaport

Hale

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab. 2014;16(9):827-832.

20.

Zheng

Roddick

Aghar-Jaffar

, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018;319(15):1580-1591.

21.

Dandona

Ghanim

Kuhadiya

, et al. Liraglutide as an additional treatment to insulin in patients with type 1 diabetes mellitus—a 52-week randomized double-blinded placebo-controlled clinical trial. Diabetes. 2018;67(suppl 1).

22.

Janzem

Steuber

Nisly

SA.

GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother. 2016;50(8): 656-665.

23.

Giorgino

Bonadonna

Gentile

, et al. Treatment intensification in patients with inadequate glycemic control on basal insulin: rational and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev. 2016;32:497-511.

24.

Pozzilli

Leslie

Peters

, et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4, and -5 trials. Diabetes Obes Metab.2018;20(6):1490-1498.

25.

ClinicalTrials.gov. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). https://clinicaltrials.gov/ct2/show/NCT01394952. Accessed March 5, 2019.

26.

Nainggolan

REWIND: once-weekly GLP-1 agonist cuts CVD in type 2 diabetes. Medscape. November 5, 2018. https://www.medscape.com/viewarticle/904373. Accessed March 5, 2019.

27.

Marso

Bain

Consoli

, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.

28.

Nayak

Govindan

Baskar

Kalupahana

Singh

BM.

Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM. 2010;103(9):687-694.

29.

Lane

Weinrib

Rappaport

. The effect of liraglu-tide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther.2011;13(5):592-595.

30.

Harris

McCarty

. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab.2015;6(1):3-18.

31.

Filippatos

Panagiotopoulou

Elisaf

MS.

Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3):202-230.

32.

McKay

Galante

Daniels

Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats. J Neurosci. 2014;34:16417-16423.

33.

Brady

Kane

Busch

RS.

GLP-1 agonist use in a patient with an explainable cause of pancreatitis. AACE Clinical Case Rep. 2016;2:e82-e85.

34.

Prasad-Reddy

Isaacs

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.

35.

Egan

Blind

Dunder

, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370:794-797.

36.

Pharmacists Letter. Combination therapy with a GLP-1 agonist. https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2018/Jul/Combination-Therapy-with-a-GLP-1-Agonist-12436. Accessed March 4th, 2019.

37.

Hinnen

Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum. 2017;30(3):202-210.

38.

Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2018.

39.

Trulicity. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

40.

Byetta (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; February 2015.

41.

Byetta. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

42.

Bydureon (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2018.

43.

Bydureon BCise (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.

44.

Bydureon. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

45.

Victoza (liraglutide) [prescribing information]. Plains-boro, NJ: Novo Nordisk Inc; August 2017.

46.

Victoza. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

47.

Adlyxin (lixisenatide) [prescribing information]. Bridge-water, NJ: Sanofi-Aventis US LLC; July 2016.

48.

Adlyxin. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

49.

Ozempic (semaglutide) [product monograph]. Mis-sissauga, Ontario, Canada: Novo Nordisk Canada Inc; September 2018.

50.

Ozempic. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

51.

Soliqua (insulin glargine | lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2017.

52.

Rosenstock

Diamant

Aroda

, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial. Diabetes Care 2016;39:1579-1586.

53.

Soliqua. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.

54.

Xultophy (insulin degludec | liraglutide) [prescribing information]. Bagsvaerd, Denmark: Novo Nordisk A/S; November 2016.

55.

Xultophy. Redbook. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. http://www.micromedexsolutions.com. Accessed March 5, 2019.